Table 2.
Estimated Proportion of Projects by Topic and Fiscal Year (FY) Based on Their Exposuresa.
| Rank | Topic | FY2012 % (95% CI) |
FY2013 % (95% CI) |
FY2014 % (95% CI) |
FY2015 % (95% CI) |
FY2016 % (95% CI) |
FY2017 % (95% CI) |
Average % (95% CI) |
p-trendb |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Other or unclear | 56.9 (51.6, 62.1) |
52.7 (46.9, 58.4) |
52.3 (46.7, 57.7) |
57.7 (52.5, 62.7) |
59.8 (55.2, 64.2) |
55.1 (49.8, 60.2) |
55.7 (53.5, 57.8) |
0.48771 |
| 2 | Genetics | 27.7 (22.8, 33.2) |
31.0 (25.5, 37.0) |
24.6 (20.1, 29.7) |
30.1 (25.1, 35.6) |
25.9 (21.8, 30.5) |
22.6 (18.8, 27.0) |
26.9 (24.9, 28.9) |
0.09479 |
| 3 | Education/ counseling |
12.9 (10.9, 15.1) |
13.3 (10.6, 16.5) |
15.3 (12.5, 18.6) |
12.9 (11.0, 15.1) |
15.7 (13.5, 18.1) |
15.3 (12.4, 18.7) |
14.3 (13.2, 15.4) |
0.14592 |
| 4 | Medication/device | 6.9 (4.6, 10.2) |
7.0 (4.4, 10.8) |
15.7 (11.5, 21.2) |
8.8 (6.3, 12.2) |
7.3 (5.9, 9.0) |
11.9 (8.2, 17.0) |
9.8 (8.4, 11.4) |
0.19599 |
| 5 | Diet/nutrition | 6.5 (4.5, 9.1) |
3.9 (2.9, 5.1) |
5.7 (3.6, 8.9) |
4.4 (3.4, 5.7) |
4.9 (3.8, 6.3) |
5.6 (3.9, 8.2) |
5.2 (4.5, 6.0) |
0.76013 |
| 6 | Healthcare delivery | 5.8 (4.0, 8.2) |
3.3 (2.4, 4.4) |
4.3 (2.7, 6.6) |
3.7 (2.8, 4.8) |
3.6 (2.7, 4.7) |
4.9 (3.2, 7.4) |
4.3 (3.6, 5.0) |
0.61019 |
| 7 | Infectious disease | 3.3 (1.8, 6.1) |
2.0 (1.4, 2.9) |
5.9 (3.7, 9.4) |
3.6 (2.7, 4.7) |
4.4 (2.6, 7.3) |
3.1 (2.3, 4.2) |
3.8 (3.1, 4.6) |
0.69820 |
| 8 | Policy/built environment |
3.6 (2.7, 4.7) |
3.8 (2.8, 5.0) |
2.7 (2.0, 3.6) |
2.8 (2.1, 3.8) |
4.6 (3.6, 5.9) |
4.7 (3.6, 6.0) |
3.7 (3.3, 4.1) |
0.07446 |
| 9 | Chemical/toxin | 2.6 (1.8, 3.6) |
3.7 (1.9, 6.8) |
4.3 (2.4, 7.5) |
3.9 (2.9, 5.2) |
2.8 (2.1, 3.9) |
2.8 (2.0, 3.8) |
3.4 (2.8, 4.1) |
0.73134 |
| 10 | Tobacco | 2.4 (1.7, 3.4) |
5.2 (2.9, 9.3) |
2.3 (1.0, 5.1) |
1.5 (0.9, 2.3) |
2.3 (1.7, 3.2) |
2.4 (1.7, 3.4) |
2.6 (2.1, 3.4) |
0.08577 |
a
Tabled values are estimated proportions and 95% CI of NIH projects funded as grants or collaborative agreements that supported primary and secondary prevention research in humans, as well as related methods research for FY2012–2017, based on the exposures coded for each project. The topics are ranked based on average proportion of prevention projects coded for each exposure and the table presents the top ten; the complete table is provided in Appendix Table 2.
b
With 128 tests for trend, the test is significant only if p-trend<0.00039.